TKT and chronic myelogenous leukemia, BCR-ABL1 positive: Nowadays, the standard of care for patients with CML is represented by TK inhibitors (TKI activity) which inhibit the constitutive activation and subsequent proliferative functions of the onco-protein [3–8].